Gilead Sciences, Inc. $GILD Shares Purchased by NewSquare Capital LLC

NewSquare Capital LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.8% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 59,027 shares of the biopharmaceutical company’s stock after buying an additional 2,701 shares during the period. NewSquare Capital LLC’s holdings in Gilead Sciences were worth $6,466,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Brighton Jones LLC raised its position in shares of Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after acquiring an additional 2,450 shares in the last quarter. Bison Wealth LLC acquired a new stake in Gilead Sciences during the 4th quarter worth approximately $215,000. Golden State Wealth Management LLC raised its position in Gilead Sciences by 14.5% during the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company’s stock worth $97,000 after buying an additional 109 shares during the last quarter. Strategic Blueprint LLC lifted its position in Gilead Sciences by 15.6% in the first quarter. Strategic Blueprint LLC now owns 3,179 shares of the biopharmaceutical company’s stock valued at $356,000 after purchasing an additional 429 shares during the period. Finally, World Investment Advisors lifted its holdings in Gilead Sciences by 7.7% in the first quarter. World Investment Advisors now owns 26,361 shares of the biopharmaceutical company’s stock valued at $2,954,000 after acquiring an additional 1,874 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the completion of the transaction, the chief executive officer owned 581,203 shares of the company’s stock, valued at $69,389,826.17. This represents a 1.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $295,200.00. Following the completion of the sale, the chief financial officer directly owned 157,055 shares in the company, valued at $18,545,054.40. This represents a 1.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 71,500 shares of company stock valued at $8,336,040 over the last quarter. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Up 1.9%

Gilead Sciences stock opened at $122.05 on Tuesday. Gilead Sciences, Inc. has a 52 week low of $86.08 and a 52 week high of $124.61. The stock has a market cap of $151.44 billion, a PE ratio of 24.31, a P/E/G ratio of 0.81 and a beta of 0.34. The stock has a 50-day moving average price of $115.81 and a 200 day moving average price of $111.78. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. During the same quarter in the previous year, the business posted $2.02 earnings per share. The company’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be issued a dividend of $0.79 per share. The ex-dividend date is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on GILD. UBS Group lifted their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Citigroup boosted their target price on Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Wednesday, October 8th. Royal Bank Of Canada upped their target price on Gilead Sciences from $100.00 to $105.00 and gave the company a “sector perform” rating in a report on Friday. Finally, The Goldman Sachs Group lifted their price target on Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $124.65.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.